Suven Pharmaceuticals Ltd (SUVENPHAR)
₹880.3▲1.52%
Analyst Rating
based on 2 analysts
50.00%
Buy
0.00%
Hold
50.00%
Sell
Based on 2 analysts offering long term price targets for Suven Pharmaceuticals Ltd. An average target of ₹670.5
Source: S&P Global Market Intelligence
Suven Pharmaceuticals Ltd Share analysis
Source: S&P Global Market Intelligence
Performance
Day's Low
Day's High
₹855.4₹884.952 Week's Low
52 Week's High
₹480₹889.7
| Returns % | |
| 1 Month Return | + 24 % |
| 3 Month Return | + 35.17 % |
| 1 Year Return | + 79.34 % |
| Market Stats | |
| Previous Close | ₹867.10 |
| Open | ₹855.40 |
| Volume | 4.98L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹22,073.33Cr |
Key Statistics
| P/E Ratio | 73.42 |
| PEG Ratio | -16.92 |
| Market Cap | ₹22,073.33 Cr |
| P/B Ratio | 8.38 |
| EPS | 11.8 |
Peer Comparison
Company Information
Share Price: ₹880.30 per share as on 24 Jul, 2024 04:01 PM
Market Capitalisation: ₹22,073.33Cr as of today
Revenue: ₹252.93Cr as on March 2024 (Q1 24)
Net Profit: ₹53.37Cr as on March 2024 (Q1 24)
Listing date: 05 Mar, 2020
Chairperson Name: Annaswamy Vaidheesh
| Organisation | Suven Pharmaceuticals Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
What's happening today
Today's Timeline - Invalid Date
07:59 AM
-Suven Pharmaceuticals receives observation letter with no adverse observations from BSE and NSE in relation to the Scheme of Amalgamation.
Key events for Suven Pharmaceuticals Ltd
Suven Pharma Receives Observation Letter for Amalgamation Scheme - 24 Jul, 2024
Suven Pharmaceuticals has received an observation letter with no adverse observations from both BSE and NSE regarding its Scheme of Amalgamation.
CCI Approves Platinum Poppy's Acquisition of Berhyanda Shares - 19 Jul, 2024
The CCI has approved the acquisition of ordinary shares of Berhyanda Limited and Berhyanda MidCo Limited by Platinum Poppy C 2024 RSC Limited, enabling it to secure an indirect non-voting economic interest in Suven Pharmaceuticals Limited.
Suven Pharma Acquires Stake in Sapala Organics, Receives Form 483 from USFDA - 15 Jul, 2024
Suven Pharmaceuticals has acquired a 51% stake in Sapala Organics and received a Form 483 with two procedural observations from the US FDA after an inspection of its subsidiary, Casper Pharma. The impact on Suven Pharma's stock remains to be seen.
Suven Pharmaceuticals VP presents paper on Green Chemistry - 12 Jul, 2024
Metlapalli Srinivasu, VP of EHS and ESG at Suven Pharmaceuticals Ltd presented a paper on the importance of green chemicals in the pharmaceutical industry at an event organized by FTCCI's Environment Committee. The usage of green chemicals is gaining importance as it is less hazardous to human health and the environment.
Analysts recommend buying Suven Pharmaceuticals Ltd - 28 Jun, 2024
Analysts suggest buying Suven Pharma at the current market price of Rs 729, with upside targets of Rs 795 and Rs 860 in the next 3-5 weeks. Place a stop loss of Rs 662.
Insights on Suven Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 9.54% to 9.80% in Jun 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 234.16 Cr → 269.98 Cr (in ₹), with an average increase of 13.3% per quarter
- POSITIVE IMPACT
Price Rise
In the last 1 month, SUVENPHAR stock has moved up by 24.0%
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 46.75 Cr → 53.37 Cr (in ₹), with an average increase of 12.4% per quarter
NO EFFECTAgainst Peers
In the last 1 year, Zydus Lifesciences Ltd has given 87.2% return, outperforming this stock by 7.8%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 50.10% of holdings in Jun 2024 quarter
- NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 127.7% return, outperforming this stock by 54.1%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 23.10% to 22.67% in Jun 2024 quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 15.26% to 14.78% in Jun 2024 quarter
Company Financials
| Q'1 24 | Q/Q Change | |
|---|---|---|
Revenue | ₹252.93Cr | ↑15.06% |
Net Income | ₹53.37Cr | ↑14.16% |
Net Profit Margin | 21.10% | ↓0.80% |
| 2024 | Y/Y Change | |
|---|---|---|
Revenue | ₹1,051.35Cr | ↓21.56% |
Net Income | ₹300.28Cr | ↓26.99% |
Net Profit Margin | 28.56% | ↓6.94% |
| 2024 | Y/Y Change | |
|---|---|---|
Total Assets | ₹2,244.38Cr | ↑14.52% |
Total Liabilities | ₹188.48Cr | ↓10.40% |
| 2024 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | ₹370.65Cr | ↓24.79% |
Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 50.1% | 0.00 | |
| Foreign Institutions | 9.8% | 2.68 | |
| Mutual Funds | 14.78% | ||
| Retail Investors | 22.67% | ||
| Others | 2.65% | 33.19 |
Key Indicators
Suven Pharmaceuticals Ltd Valuation
Suven Pharmaceuticals Ltd in the last 5 years
Lowest (4.48x)
March 30, 2020
Industry (56.07x)
July 23, 2024
Today (73.42x)
July 23, 2024
Highest (73.86x)
July 18, 2024
Earnings and Dividends
Suven Pharmaceuticals Ltd Earnings Results
Suven Pharmaceuticals Ltd’s net profit fell -56.95% since last year same period to ₹53.37Cr in the Q4 2023-2024. On a quarterly growth basis, Suven Pharmaceuticals Ltd has generated 14.16% jump in its net profits since last 3-months.
Read More about Earnings ResultsSuven Pharmaceuticals Ltd Dividends September,2022
In the quarter ending June 2022, Suven Pharmaceuticals Ltd has declared dividend of ₹1 - translating a dividend yield of 1.27%.
Read More about Dividends
Technicals Summary
Bearish
Neutral
Bullish
Suven Pharmaceuticals Ltd is currently in a Bullish trading position according to technical analysis indicators.
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Suven Pharmaceuticals Ltd shares.
Suven Pharmaceuticals Ltd (SUVENPHAR) share price today is ₹880.3
Suven Pharmaceuticals Ltd is listed on NSE
Suven Pharmaceuticals Ltd is listed on BSE
- Today’s highest price of Suven Pharmaceuticals Ltd is ₹884.9.
- Today’s lowest price of Suven Pharmaceuticals Ltd is ₹855.4.
PE Ratio of Suven Pharmaceuticals Ltd is 73.42
PE ratio = Suven Pharmaceuticals Ltd Market price per share / Suven Pharmaceuticals Ltd Earnings per share
Today’s traded volume of Suven Pharmaceuticals Ltd(SUVENPHAR) is 4.98L.
Today’s market capitalisation of Suven Pharmaceuticals Ltd(SUVENPHAR) is ₹22073.33Cr.
| Suven Pharmaceuticals Ltd(SUVENPHAR | Price |
|---|---|
52 Week High | ₹889.7 |
52 Week Low | ₹480 |
Suven Pharmaceuticals Ltd(SUVENPHAR) share price is ₹880.3. It is down -1.06% from its 52 Week High price of ₹889.7
Suven Pharmaceuticals Ltd(SUVENPHAR) share price is ₹880.3. It is up 83.40% from its 52 Week Low price of ₹480
| Suven Pharmaceuticals Ltd(SUVENPHAR | Returns |
|---|---|
1 Day Returns | 13.2% |
1 Month Returns | 24% |
3 Month Returns | 35.17% |
1 Year Returns | 79.34% |